Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECZTRA 4: Tralokinumab DDI in Atopic Dermatitis
NCT03556592Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Aug 2018
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of tralokinumab in atopic dermatitis (AD), sponsored by LEO Pharma. Primary endpoints: Ratio of the AUC-last at Week 15 to Day -7 and Ratio of the Cmax at Week 15 to Day -7. Started Aug 2018; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03556592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03556592.